Moreover, it has been reported that the extent of optimal tumor-free margin may vary according to the KRAS mutation status [33], with 1–4 mm margins being considered sufficient in patients with wild-type KRAS, whereas 1-cm margins being considered insufficient for those with mutant KRAS status. This evidence concerns the gene KRAS and neoplasm.